Modifications of low-molecular weight heparin use in a French University Hospital after implementation of new guidelines

Drug Safety

Volumn 30, Issue 5, 2007, Pages 409-417

  Leclerc Foucras, Sophie ^a,b   Bagheri, Haleh ^a,b   Samii, Kamran ^a   Montastruc, Jean Louis ^a,b   Lapeyre Mestre, Maryse ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; CEPHALOSPORIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TINZAPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MONITORING; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOSIS; TREATMENT DURATION; UNIVERSITY HOSPITAL;

AGED; ANTICOAGULANTS; DRUG UTILIZATION; FEMALE; FRANCE; GUIDELINE ADHERENCE; HEMORRHAGIC DISORDERS; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALS, UNIVERSITY; HUMANS; LENGTH OF STAY; MALE; PRESCRIPTIONS, DRUG; RENAL INSUFFICIENCY;

EID: 34248378122     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730050-00004     Document Type: Article

References (21)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188-203S
2. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401-28S
3. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thomboembolism. Adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000; 160: 334-40
4. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338-400
5. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800
6. Ambrosi P, Calise G, Villani P, et al. Questionnaire on venous thromboembolism prevention by low molecular weight heparin in medical environment. Presse Med 2000; 29: 1447-50
7. Geerts WH. Strength of evidence for low-molecular-weight heparin. Chest 2002; 6: 2078-9
8. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81
9. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of Low Molecular Weight Heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26: 197-207
10. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 2005; 28: 333-49
11. Agence Française de Sécurité Sanitaire des Produits de Santé. Centre Midi-Pyrénées de Pharmacovigilance - Toulouse, 1999/2001. Enquête nationale de Pharmacovigilance sur les HBPM Centre Midi-Pyrénées de Pharmacovigilance - Toulouse Les données de 2 enquetes nationales de pharmacovigilance, réalisées en 1999 et 2001 [online]. Available from URL: http://agmed.sante.gouv.fr/htm/10/hpbm/hbpmtoul.pdf [Accessed 2007 Mar 27]
12. French Health Products Safety Agency. Information to prescribers about low-molecular-weight heparin [online]. Available from URL: http://www.agmed. sante.gouv.fr [Accessed 2006 Dec 20]
13. Maguire P, Selby P. Assessing the quality of life in cancer patients. Br J Cancer 1989; 60: 437-40
14. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-50
15. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-5
16. Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002; 122: 108-14
17. Belmin J, Medjahed S, Trivalle C, et al. Heparin use in geriatrics and risk profiles of treated patients: a surbey in France. Groupe de Recherche sur l'Héparine en Gériatrie (GREHG). Presse Med 2001; 30:101-6
18. Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res 2000; 100 (2): V113-20
19. Fagot JP, Flahault A, Fodil M, et al. Prophylactic prescription of low-molecular-weight heparin in the non-surgical setting: impact of recommendations. Presse Med 2001; 30: 203-8
20. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-63
21. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54